American Chemical Society
jm058042r_si_001.pdf (195.73 kB)

Enantioselective Nonsteroidal Aromatase Inhibitors Identified through a Multidisciplinary Medicinal Chemistry Approach

Download (195.73 kB)
journal contribution
posted on 2005-11-17, 00:00 authored by Andrea Cavalli, Alessandra Bisi, Carlo Bertucci, Carlo Rosini, Anja Paluszcak, Silvia Gobbi, Egidio Giorgio, Angela Rampa, Federica Belluti, Lorna Piazzi, Piero Valenti, Rolf W. Hartmann, Maurizio Recanatini
To identify enantioselective nonsteroidal aromatase inhibitors, a multidisciplinary medicinal chemistry approach was pursued. First, our earlier CoMFA model [Bioorg. Med. Chem. 1998, 6, 377−388] was extended taking purposely into account previously discovered enantioselective aromatase inhibitors. The 3D QSAR model was then exploited to design chiral ligands, whose configurational assignment was obtained, after HPLC separation, by means of a combination of circular dichroism measurements and time dependent density functional calculations. Finally, the new enantiomeric inhibitors were separately tested to ascertain both their potency against the cytochrome P450 aromatase (CYP19; EC, and their selectivity relative to another enzyme of the P450 family. A satisfactory agreement between experimental and predicted data allowed us to assert that a properly built “enantioselective CoMFA model” might constitute a useful tool for addressing enantioselective ligands design.